Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease

Archives of Neurology

Volumn 68, Issue 7, 2011, Pages 925-931

  Godau, Jana ^a   Knauel, Katharina ^a   Weber, Karin ^b   Brockmann, Kathrin ^a   Maetzler, Walter ^a   Binder, Gerhard ^b   Berg, Daniela ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; B SCAN; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DOPAMINERGIC SYSTEM; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 79960189743     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.129     Document Type: Article

References (33)

1. Schapira AH. Progress in neuroprotection in Parkinson's disease. Eur J Neurol. 2008;15(suppl 1):5-13. (Pubitemid 351421303)
2. Berg D. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. J Neural Transm Suppl. 2006;(71):123-132.
3. Berg D. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis. 2008;5(3-4):133-136.
4. Piccini P, Whone A. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol. 2004;3(5):284-290. (Pubitemid 38510199)
5. Stiasny-Kolster K, Doerr Y, Möller JC, et al. Combination of "idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128(pt 1):126-137. (Pubitemid 40070527)
6. Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol. 2008;7(5):417-424.
7. Ruprecht-Dörfler P, Klotz P, Becker G, Berg D. Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. Parkinsonism Relat Disord. 2007;13(6):362-364. (Pubitemid 47212783)
8. Berg D, Roggendorf W, Schröder U, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002;59(6):999-1005. (Pubitemid 34640761)
9. Liepelt I, Behnke S, Schweitzer K, et al. Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population [published online November 6, 2009]. Neurobiol Aging.
10. Landi F, Capoluongo E, Russo A, et al. Free insulin-like growth factor-I and cognitive function in older persons living in community. Growth Horm IGF Res. 2007;17(1):58-66.
11. Breese CR, Ingram RL, Sonntag WE. Influence of age and long-term dietary restriction on plasma insulin-like growth factor-1 (IGF-1), IGF-1 gene expression, and IGF-1 binding proteins. J Gerontol. 1991;46(5):B180-B187.
12. Godau J, Herfurth M, Kattner B, Gasser T, Berg D. Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(5):536-538.
13. Mashayekhi F, Mirzajani E, Naji M, Azari M. Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease. J Clin Neurosci. 2010;17(5):623-627.
14. Tuncel D, Inanc Tolun F, Toru I. Serum insulin-like growth factor-1 and nitric oxide levels in Parkinson's disease. Mediators Inflamm. 2009;2009:132464. doi: 10.1155/2009/132464.
15. Schaefer S, Vogt T, Nowak T, Kann PH; German KIMS board. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy. J Neuroendocrinol. 2008;20(1):104-109. (Pubitemid 350239154)
16. Martignoni E, Horowski R, Liuzzi A, et al. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo. Clin Neuropharmacol. 1996;19(1):72-80. (Pubitemid 26026323)
17. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33-39. (Pubitemid 29046907)
18. Louis ED, Schupf N, Manly J, Marder K, Tang MX, Mayeux R. Association between mild parkinsonian signs and mild cognitive impairment in a community. Neurology. 2005;64(7):1157-1161.
19. Louis ED, Tang MX, Schupf N, Mayeux R. Functional correlates and prevalence of mild parkinsonian signs in a community population of older people. Arch Neurol. 2005;62(2):297-302. (Pubitemid 40204752)
20. Racette BA, Good LM, Kissel AM, Criswell SR, Perlmutter JS. A population-based study of parkinsonism in an Amish community. Neuroepidemiology. 2009;33(3):225-230.
21. Liepelt I, Wendt A, Schweitzer KJ, et al. Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population. J Neural Transm. 2008;115(7):993-999.
22. Godau J, Berg D. Role of transcranial ultrasound in the diagnosis of movement disorders. Neuroimaging Clin North Am. 2010;20(1):87-101.
23. Blum WF, Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regul. 1994;4(suppl 1):11-19.
24. Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994;78(3):744-752. (Pubitemid 24083322)
25. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 1995;80(8):2534-2542.
26. Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett. 2001;316(3):129-132. (Pubitemid 34020746)
27. Guan J, Krishnamurthi R, Waldvogel HJ, Faull RL, Clark R, Gluckman P. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res. 2000;859(2):286-292. (Pubitemid 30136100)
28. Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain. 2005;128(pt 12):2777-2785. (Pubitemid 41746632)
29. Patel AV, Cheng I, Canzian F, et al; Breast and Prostate Cancer Cohort Consortium. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008;3(7):e2578. doi:10.1371/journal.pone. 0002578.
30. Vella A, Bouatia-Naji N, Heude B, et al. Association analysis of the IGF1 gene with childhood growth, IGF-1 concentrations and type 1 diabetes. Diabetologia. 2008;51(5):811-815.
31. Holzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003;421(6919):182-187. (Pubitemid 36090987)
32. Salehi Z, Mashayekhi F, Naji M. Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. Biofactors. 2008;33(2):99-106.
33. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM. Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis. 2007;12(4):285-290.